tazemetostat hydrobromide

{
  "id": "MLC-T-ONC-008538",
  "term": "tazemetostat hydrobromide",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults and children aged 16 years and older with a rare type of soft tissue sarcoma called epithelioid sarcoma and adults with certain types of follicular lymphoma. It is also being studied in the treatment of other types of cancer. Tazemetostat hydrobromide blocks certain enzymes involved in gene expression and cell division. Blocking these enzymes may help keep cancer cells from growing. Tazemetostat hydrobromide is a type of histone methyltransferase inhibitor. Also called Tazverik.",
    "The hydrobromide salt form of tazemetostat, an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation."
  ],
  "synonyms": [
    "Tazverik",
    "EPZ-6438 monohydrobromide",
    "tazemetostat monohydrobromide"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tazemetostat-hydrobromide/"
}